Please Login


Cancel
Become a Member | Why Join?
  • I am an Individual
    • I am an Individual
    • I Work in Industry
    • I Work in Healthcare
    • I Work in Education

Anaphylaxis Campaign

Supporting people at risk of severe allergies

DonateEMERGENCY INSTRUCTIONS

  • Who We Are
    • Our Team
    • Our Ambassadors
    • Vacancies
  • Media Centre
    • Latest News
    • Press Releases
    • Your Stories
    • Facts and Figures
    • Media Toolkit
  • Contact Us
    • Anaphylaxis Campaign’s Helpline
    • Helpline FAQs
    • Keep In Touch
    • Share Your Story
  • 0 items£0.00
  • Home
  • What is Anaphylaxis
    • 14 Major Allergens
    • Signs and Symptoms
    • Glossary Of Terms
  • Living with Anaphylaxis
    • Care and Medication
    • Infant Weaning Guidance
    • Guidance for Young Adults
      • Managing Allergens at University
      • Easy to ASK Campaign
      • #TakeTheKit
      • Meet our Youth Ambassador
    • Shopping and Preparing Food
    • A Guide to Eating Out
      • Anaphylaxis Campaign welcomes ‘Natasha’s Law’
    • Travelling
      • Booking your Flight
      • The Day of your Flight
      • Preparing to Travel
      • When Abroad
      • Airline Allergy Policies
      • Translation Cards
      • Travel Insurance
      • Allergy Organisations Abroad
    • Seasonal Events
      • Diwali
      • Valentine’s Day
      • Mother’s Day
      • Easter
      • Father’s Day
      • Summer Festivals
      • Halloween
      • Christmas
    • Living with Natural Rubber (NRL) Allergy
      • Latex Allergy and The Law
      • Latex Allergy Forum
      • NRL and the Workplace
    • The NHS
  • Support Us
    • Donate
      • Make a One-Off Donation
      • Make a Regular Donation
      • Gift Aid your Donations
      • Give as you Shop
      • Give through your Salary
      • Give in Celebration
      • Give in Memory
      • Leave a Gift in your Will
      • Charitable Donations and Grants
    • Fundraising
      • Register your Fundraising Plans
      • Fundraising events
      • Awareness and Fundraising in Schools
    • Membership
    • Volunteer
      • Allergy Buddy
      • Community Volunteer
      • Media Volunteers
      • Volunteer as a Lay Reviewer
      • Volunteer at our Head Office
  • Events
    • Conferences
    • Healthcare Industry Events
    • Food Industry Events
    • Upcoming Webinars
  • Information & Training
    • Anaphylaxis Training
      • Allergywise Training Courses
      • For Parents and Carers of Severely Allergic Children
      • For Adults with Severe Allergies
      • For Schools
      • For Families and Carers of Pre-School Children
      • For Pharmacists
      • For Healthcare Professionals
      • For GPs and Practice Nurses
      • For Careworkers
    • Factsheets
    • Knowledgebase
    • Our Webinars
    • Allergy Alerts
    • Support Groups
    • Our Posters
    • Useful Links
    • Facts and Figures
    • Research
  • Campaigning
    • Making Schools Safer Project 2020
      • Spare Pens in Schools
      • #TakeTheKit
    • Guidance for Young Adults
      • Managing Allergens at University
      • Easy to ASK Campaign
      • #TakeTheKit
    • Anaphylaxis Guidance For All
      • Managing Allergens in the Workplace
      • Always Carry Two Adrenaline Auto-Injectors
      • Prescription Charges Coalition
      • Anaphylaxis Information Matters (AIM)
  • Tried and Trusted Reviews
  • COVID-19 advice
    • Covid-19 Vaccines and Allergies
    • COVID-19 FAQs
    • Tips For Parents
    • Coronavirus & Allergy Webinar
  • Shop
  • Meet our Ambassador

Allergy Therapeutics and Imperial College London start Peanut Allergy Study

6th January 2021 by anaphylaxis

Allergy Therapeutics PLC – Sussex-based biotechnology firm focused on allergy vaccines – Initiates peanut allergy biomarker study with Imperial College London to confirm potential of novel peanut vaccine candidate. The study aims to evaluate the novel virus like particle based peanut allergy vaccine candidate, to confirm its hypoallergic potential and its potent immune response. Submission of an application to the US Food & Drug Administration for study is expected in 2021.

Allergy Therapeutics said its peanut allergy vaccine programme was supported by a “strong” preclinical research package, providing preclinical proof of concept for sustained immunity and protection against peanut anaphylaxis after a single vaccination.

It said that importantly, in contrast to current treatment approaches such as desensitisation via oral administration or transdermal patches, which required daily dosing over several years, it was expected that its next-generation VLP-based peanut vaccine candidate would use three injections to induce sustained protection.

“A safe and effective short-course peanut allergy vaccine would be a significant breakthrough product, offering life-changing benefits to sufferers affected by this condition. The data we have generated so far for our peanut vaccine candidate give us confidence in its potential and through this study we have an opportunity to build on that confidence and provide our upcoming Phase I study with the greatest chances of success,” says Chief Executive Officer Manuel Llobet.

Filed Under: News

Head Office

1 Alexandra Road
Farnborough
Hampshire
GU14 6BU

General Enquiries

  • +44 (0) 1252 546100
  • [email protected]

Helpline

  • +44 (0) 1252 542029
  • [email protected]

Press Office

  • +44 (0) 1252 893864
    +44 (0) 7393 234092
  • [email protected]

Fundraising

  • +44 (0) 1252 893850
  • [email protected]

Get Social

  • © Anaphylaxis Campaign 2019
  • Terms & Conditions |
  • Privacy & Cookies Policy |
  • Fundraising Policy |
  • Feedback Policy |
  • Complaints Procedure

Anaphylaxis Campaign (incorporating the Latex Allergy Support Group), a charity registered in England and Wales (1085527) and a registered company limited by guarantee in England and Wales (04133242).
Our registered company address is Anaphylaxis Campaign, 1 Alexandra Road, Farnborough, GU14 6BU.